You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Review: atenolol may be ineffective for reducing cardiovascular morbidity or all cause mortality in hypertension

https://doi.org/10.1136/ebm.10.3.74

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet 2004;364:1684–9.
    OpenUrlCrossRefPubMedWeb of Science

    
 
 Q In patients with essential hypertension, does atenolol reduce cardiovascular morbidity or all cause mortality?

    Clinical impact ratings GP/FP/Primary care ★★★★★★☆ IM/Ambulatory care ★★★★★★★ Cardiology ★★★★★☆☆

    METHODS

    Embedded ImageData sources:

    Cochrane Library, Medline, relevant textbooks, and researchers in hypertension.

    Embedded ImageStudy selection and assessment:

    randomised controlled trials (RCTs) that assessed the effect of atenolol (as the sole first line drug in 1 of the treatment groups) on cardiovascular morbidity or mortality in patients with essential hypertension.

    Embedded ImageOutcomes:

    myocardial infarction (MI), stroke, cardiovascular mortality, and all cause mortality.

    MAIN RESULTS

    8 RCTs met the selection criteria. 2 major comparisons were made. Atenonol compared with placebo or with untreated controls (4 RCTs, n = 6825). Mean reduction in blood pressure (BP) …

    View Full Text

    Footnotes

    • For correspondence: Professor L H Lindholm, Umeå University Hospital, Umeå, Sweden. larshlindholmfammed.umu.se

    • Source of funding: not stated